BridgeMD
Compares treatment options for Malaria
Official title ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
ClinicalTrials.gov ID: NCT05788094
What this study is testing
What is Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)?
Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose) is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for malaria.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In this area of Greater Mekong Subregion (GMS), vivax malaria is the most common kind of malaria. It can stay very long in the liver, and come out later to make another episode of illness.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients with P. vivax mono-infection as diagnosed by Rapid Diagnostic Test
- Fever or history of fever in the previous 7 days
- Quantitative G6PD activity ≥70% of the population median i.e., ≥6.1U/gHb
- Age \> 18 years, Weight \>35 kg
- Ability to understand the study instructions and provide informed consent
You likely can't join if
- Coincident P. falciparum malaria or other infections
- Pregnancy
- Lactation
- Hb \< 8 g/dL
- Quantitative G6PD activity \<70% of the population median i.e., \<6.1U/gHb
- Severe malaria (as per WHO guideline)
See the full eligibility criteria
- Patients with P. vivax mono-infection as diagnosed by Rapid Diagnostic Test
- Fever or history of fever in the previous 7 days
- Quantitative G6PD activity ≥70% of the population median i.e., ≥6.1U/gHb
- Age \> 18 years, Weight \>35 kg
- Ability to understand the study instructions and provide informed consent
- Willing to be followed for 4 months and likely to adhere to the study protocol.
- Coincident P. falciparum malaria or other infections
- Pregnancy
- Lactation
- Hb \< 8 g/dL
- Quantitative G6PD activity \<70% of the population median i.e., \<6.1U/gHb
- Severe malaria (as per WHO guideline)
- History of allergic or haemolytic response to any of the study drugs
The study team makes the final eligibility decision.
Where it's taking place
- Mae Sot, Changwat Tak, Thailand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mae Sot, Changwat Tak, Thailand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.